Allergy Therapeutics (LON:AGY) Issues Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) released its earnings results on Tuesday. The company reported GBX (0.38) EPS for the quarter, Digital Look Earnings reports. The business had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a negative net margin of 72.91% and a positive return on equity of 227.10%.

Allergy Therapeutics Price Performance

Shares of AGY stock remained flat at GBX 10.30 during trading hours on Thursday. 71,346 shares of the stock traded hands, compared to its average volume of 280,355. Allergy Therapeutics has a 1 year low of GBX 5 and a 1 year high of GBX 12.10. The company has a debt-to-equity ratio of -213.13, a quick ratio of 1.48 and a current ratio of 1.28. The firm has a market cap of £652.25 million, a PE ratio of -12.26, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The stock has a 50-day moving average price of GBX 10.96 and a two-hundred day moving average price of GBX 10.04.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.